Sangamo (SGMO) Q4 2025 earnings review
Clinical Milestones Hit, But The Cash Clock Is Ticking Loudly
Sangamo delivered strong clinical progress in Q4, initiating the rolling BLA submission for its Fabry disease gene therapy (ST-920) and activating six sites for its core neurology pain study (ST-503). However, the financials paint a highly distressed picture. Q4 net loss widened to $37.4M as a $13.2M asset impairment and BLA readiness costs caused operating expenses to spike. The company ended 2025 with just $20.9M in cash, requiring a $25M emergency equity raise in February 2026 just to extend operations into Q3 2026. The entire investment thesis rests on management's ability to secure a Fabry commercialization partnership before liquidity dries up entirely.
🐂 Bull Case
The rolling BLA submission for ST-920 is officially underway, backed by a highly compelling +1.965 annualized eGFR slope at 52-weeks. If a partner is secured, this is a near-commercial asset with massive upside.
Sangamo is executing on its clinical-stage neurology transition. The FDA granted Fast Track Designation to ST-503 (chronic neuropathic pain), and six clinical sites are now active for the Phase 1/2 STAND study.
🐻 Bear Case
Ending the year with just $20.9M in cash forced a highly dilutive $25M equity raise post-close. The runway only extends to Q3 2026, leaving zero margin for error.
Potential pharma partners are fully aware of Sangamo's ticking clock. This dynamic heavily risks forcing management into a sub-optimal, heavily discounted licensing deal for their crown jewel Fabry asset.
⚖️ Verdict: 🔴
Bearish. The underlying science and regulatory momentum are impressive, but Sangamo is backed into a financial corner. Until a non-dilutive commercialization partnership is signed, the risk of terminal dilution or bankruptcy dominates the narrative.
Key Themes
The Liquidity Tightrope
Cash burn remains the ultimate existential threat. Total cash and equivalents cratered 50% year-over-year to $20.9M. While management successfully executed a $25M underwritten offering in February 2026, this is merely a band-aid that extends the cash runway to Q3 2026. The company remains explicit about its 'going concern' risks, meaning a Fabry partnership is strictly mandatory for survival.
Fabry BLA and Companion Diagnostic Advancing
Accelerating. Sangamo is moving swiftly on the regulatory front. The rolling BLA submission for isaralgagene civaparvovec (ST-920) was initiated in December, with completion targeted as early as summer 2026. Furthermore, the company submitted an antibody assay companion diagnostic to the FDA's CDRH. This diagnostic integration creates a stronger, more defensible commercial package for prospective partners.
Operating Expense Spike Contradicts 'Lean' Narrative
Reversing. For several quarters, management pushed a narrative of strategic realignment and strict cost-cutting. However, Q4 GAAP operating expenses spiked 56% YoY to $52.4M. This was driven by a sudden $13.2M impairment charge on long-lived assets and rising manufacturing costs for Fabry BLA readiness. This proves that pushing an asset to the commercial finish line requires heavy capital, exactly when Sangamo has none.
Neurology Pipeline Maturing
Accelerating. The pivot to a neurology-first company is progressing from theory to clinical reality. The FDA granted Fast Track Designation to ST-503 (epigenetic regulator for small fiber neuropathy). With six sites now active for the Phase 1/2 STAND study, Sangamo has established a second major pillar of value alongside Fabry. Additionally, CTA-enabling activities for ST-506 (prion disease) leveraging the STAC-BBB capsid are on track.
Episodic BD Monetization
Stable. Q4 revenue jumped to $14.2M, up from $7.6M a year ago, but this was entirely dependent on partner triggers rather than recurring operations. Specifically, a $6.0M buyout option exercised by Pfizer for legacy zinc-finger cell lines drove the beat. While lumpy, it validates Sangamo's ability to extract residual cash value from its vast legacy intellectual property.
Macro Headwinds Stalling Partnership Execution
The primary roadblock to the much-needed Fabry commercialization deal appears to be macro-driven. Despite flawless clinical data (+1.965 eGFR slope at 52-weeks), the broader gene therapy commercial landscape in the U.S. remains challenged. Prospective partners are exercising extreme caution regarding pricing, payer pushback, and launch dynamics for one-time genomic medicines, stretching negotiations out and directly threatening Sangamo's timeline.
Other KPIs
Decelerating. Down significantly from $57.8 million in 2024. The $18.2 million drop was primarily driven by the absence of a $49.9 million collaboration payment from Genentech recognized in the prior year, highlighting the company's reliance on one-off milestone payments to generate the top line.
Worsening. Net loss deepened from -$97.9 million in 2024. While non-GAAP operating expenses slightly decreased year-over-year, the drop in lumpy collaboration revenues and the Q4 impairment charge pushed the bottom line further into the red.
Guidance
Decelerating. The midpoint of $130 million implies an approximate 19% reduction compared to FY25's $160.8 million. Management aims to control cash burn tightly, but this assumes no further unexpected asset impairment charges.
Decelerating. Excludes ~$8 million in stock-based compensation and ~$2 million in depreciation and amortization. The midpoint of $115 million implies a 14% decline versus FY25, reflecting the completion of certain legacy programs and the acute necessity to preserve cash.
Stable compared to immediate fears, but highly constrained. This forecast includes the $20.9 million year-end balance plus the $25 million February 2026 equity offering. This explicitly hard-codes the deadline for the Fabry commercialization partnership to the summer of 2026.
Key Questions
Contingency for Regulatory Timeline
The rolling BLA submission for ST-920 is expected to be completed by summer 2026, precisely when the extended cash runway is projected to dry up. What are the fallback financing contingency plans to fund operations during the actual FDA review period if a commercial partner is not secured beforehand?
Details on the Impairment Charge
What specifically triggered the sudden $13.2 million impairment of long-lived assets in Q4, and does the balance sheet hold any other legacy infrastructure or assets vulnerable to future write-downs?
STAND Study Timeline
With six clinical sites now activated for the Phase 1/2 STAND study evaluating ST-503 in small fiber neuropathy, what is the realistic timeline for seeing preliminary safety and efficacy dose-escalation readouts?
Diagnostic Strategy
You have submitted an antibody assay companion diagnostic to the FDA's CDRH. Is the approval of ST-920 strictly contingent on the simultaneous approval of this PMA diagnostic, or can the gene therapy proceed independently if device review is delayed?